ReviewTherapeutics and clinical risk management2020
Statin-Associated Autoimmune Myopathy: Current Perspectives.
Review in Therapeutics and clinical risk management, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 29 citations in OpenAlex.
- Statin-Related Myotoxicity: A Narrative Review and Practical Approach for General Internists.Journal of general internal medicine · 2026Review
- A severe and fatal course of statin-induced necrotizing autoimmune myopathy: a case report.Journal of medical case reports · 2026Article
- Increasing recognition of statin-associated anti-HMGCR antibody-positive autoimmune myopathy: a single-center retrospective study.Clinical rheumatology · 2026Article
- Diagnostic and Therapeutic Challenges in Statin-Induced Necrotizing Autoimmune Myopathy in an Elderly Patient: A Rare Case Report.Clinical case reports · 2026Article
- Unilateral lower limb cellulitis-like edema as an atypical cutaneous manifestation of antisynthetase syndrome: a case report and targeted literature review.Frontiers in medicine · 2026Article
- Review
- Effects of HMG CoA reductase (HMGCR) deficiency on skeletal muscle development.The FEBS journal · 2025Article
- Article
- Dermatomyositis, Rhabdomyolysis, and Statin-Induced Myopathy: A Case Report Illustrating the Spectrum of Myopathy.Cureus · 2025Article
- Effectiveness of proprotein convertase subtilisin/kexin type 9 inhibitors in managing hypercholesterolemia post-statin-associated immune-mediated necrotizing myopathy: report of five cases and literature review.Rheumatology international · 2025Review
- Statin-Induced Necrotizing Autoimmune Myopathy in a Patient With Complex Diabetes Management.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2025Article
- Trends in Reports of Statin-Associated Immune-Mediated Necrotizing Myopathy Using the Japanese Adverse Drug Event Report Database.Drugs - real world outcomes · 2025Article
- Precise identification and tracking of HMGCR-reactive CD4+ T cells in the target tissue of patients with anti-HMGCR immune-mediated necrotising myopathy.Annals of the rheumatic diseases · 2025Article
- An atorvastatin-induced positive anti-HMGCR immune-mediated necrotizing myopathy case.Clinical case reports · 2024Article
- Statin-Associated Autoimmune Myopathy Masquerading As Recurrent Falls in an Older Adult.Cureus · 2023Article
- Challenges in the diagnosis and management of immune-mediated necrotising myopathy (IMNM) in a patient on long-term statins.Rheumatology international · 2023Review
- Refractory Statin-Induced Immune-Mediated Necrotizing Myositis: Challenges and Perils in Its Management.Cureus · 2022Article
- Article
- Slowly Progressive Limb-Girdle Weakness and HyperCKemia - Limb Girdle Muscular Dystrophy or Anti-3-Hydroxy-3-Methylglutaryl-CoA-Reductase-Myopathy?Journal of neuromuscular diseases · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although generally well tolerated, statin users frequently report muscle-related side effects, ranging from self-limiting myalgias to rhabdomyolysis or the rare clinical entity of statin-associated immune-mediated necrotizing myopathy (IMNM). Statin-associated IMNM is based on the development of autoantibodies against 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate-limiting enzyme in cholesterol synthesis and the pharmacologic target of statins, and leads to a necrotizing myopathy requiring immunosuppressive therapy. This review attempts to recapitulate the diverse aspects of anti-HMGCR IMNM, including clinical presentation, diagnostic modalities, genetic risk associations, therapeutic options and potential pathogenetic pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.